Perceptive Informatics Improves the Clinical Development Process with Enhanced CTMS Technology
BOSTON, MA, August 9, 2007-Perceptive Informatics, the technology subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced the release of an enhanced version of its comprehensive clinical trial management system (CTMS) IMPACT® technology with improved site management and monitoring capabilities. With over 25,000 users in 85 countries, Perceptive Informatics’ IMPACT software is the world’s most widely used CTMS technology.
The IMPACT software comprises several Web-based modules designed to deliver practical and tangible results, decreasing the time, cost, and risk associated with the development of new products. The software provides planning and tracking support for all aspects of a clinical trial and consolidates information from various collection points into a single source. The IMPACT solution is scalable to support studies of all sizes ranging from large, multi-national studies to single center studies. The most recent version features an online and offline Web-based site management and monitoring module, called MySites, which offers 24/7/365 access from anywhere in the world, enabling work on all aspects of site management including monitoring, milestone planning, issue resolution and recruitment.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.